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Purpose: The objectives of this study were to establish and characterize a novel animal model 
of metastatic prostate cancer-induced bone pain.
Methods: Copenhagen rats were injected with 106 MATLyLu (MLL) prostate cancer cells 
or phosphate-buffered saline by per cutaneous intra femoral injections into the right hind leg 
distal epiphysis. Over 13 days, rats progressively developed a tumor within the distal femoral 
epiphysis. On days 3, 7, 10, and 13 post injection, rats were subjected to the incapacitance 
and Randall–Selitto behavioral tests as they are believed to be indirect reflections of tumor 
induced pain. Ipsilateral hind limbs were subjected to X-ray and computed tomography (CT) 
scans and histological sections were stained with hematoxylin and eosin (H&E).
Results: Intra femoral injections of MLL cells resulted in the progressive development of a 
tumor leading to bone destruction and nociceptive behaviors. Tumor development resulted in the 
redistribution of weight to the contralateral hind leg and significantly reduced the paw withdrawal 
threshold of the ipsilateral hind paw as observed via the incapacitance and Randall–Selitto tests, 
respectively. X-ray and computed tomography  scans along with H&E stains indicated tumor-
associated structural damage to the distal femur. This model was challenged with administration 
of meloxicam. Compared with vehicle-injected controls, the meloxicam-treated rats displayed 
smaller nociceptive responses as observed with the incapacitance and Randall–Selitto tests, sug-
gesting that meloxicam was effective in reducing the pain-related symptoms displayed by model 
animals and that the model behaved in a predictable way to cyclooxygenase-2 treatment.
Conclusions: This model is unique from other bone cancer models in that it is a comprehensive 
model utilizing a competent immune system with a syngeneic tumor. The model establishes a tool 
that will be useful to investigate mechanisms of cancer pain that are induced by cancer cells.
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Introduction
The skeleton is a preferred site for the metastasis of malignant tumors, particularly for 
prostate cancer.1–5 Prostate cancer remains a serious health concern for males as the 
lifetime risk is 19.8%, and it is the second leading cause of cancer-related deaths in 
men.6 The majority of males dying from prostate cancer have some form of skeletal 
involvement at death.7,8 Furthermore, skeletal metastases have been identified in 
approximately 70% of patients with breast or prostate cancer, while some form of 
skeletal metastasis has been identified in more than 90% of patients who die from 
breast or prostate cancer.8–9
Patients suffering from bone tumors frequently experience a reduced quality 
of life due to a variety of factors that include hypercalcemia, bone fractures, spinal Journal of Pain Research 2010:3 submit your manuscript | www.dovepress.com
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cord compression, and severe bone pain.3,4,6,9–17 The most 
common symptom experienced by patients with bone tumors 
is pain.3,11,12,14,18,19 Due to the incidence, the severity, and the 
impact of metastatic bone cancer pain, a project was initiated 
to develop a novel animal model. The novel bone cancer 
animal model was induced by the introduction of prostate 
cancer cells into a hind leg distal femoral epiphysis providing 
an experimental model with which to investigate mechanisms 
of bone cancer pain.
While the severity and evolution of bone pain experi-
enced by patients varies, cancer-induced bone pain (CIBP) 
is typically divided into two categories: ongoing pain and 
breakthrough or incident pain.3,20–22 Typically presenting first, 
ongoing pain is described as a constant dull or throbbing pain 
that increases in intensity over time. Ongoing pain can be 
intensified with the active use of skeletal segments affected 
by tumor.3 With the progression of bone cancer, breakthrough 
or incident pain begins to present itself. Breakthrough or 
incident pain is characterized as periodic exacerbations of 
bone pain.3,20–25 Breakthrough pain can arise spontaneously 
and be unrelated to movement or can be associated with the 
movement of tumor affected skeletal portions.13,20–22
In 1961, Dunning observed the appearance of an 
adenocarcinoma in the prostate of a male Copenhagen rat.26 
The Dunning R-3327 adenocarcinoma is a spontaneously 
developed prostate tumor derived from a male Copenhagen 
rat.27,28 The Dunning R-3327 tumor line has a doubling 
time of 15–20 days and is androgen sensitive.27 Continuous 
subcutaneous passage of the R-3327 tumor led to the pro-
duction of the rapidly growing (doubling time of approxi-
mately 2.2 days) R-3327 AT (anaplastic tumor) tumor cell 
line which is androgen insensitive with a low metastatic 
potential.26,27,29,30 At the 60th passage, the R-3327 AT tumor 
cell line displayed a high metastatic potential and increased 
growth rate (doubling time of approximately 1.5 days) and 
was renamed the MAT (metastatic-AT) tumor.27 The new 
MAT tumor cell line reproducibly resulted in the metastatic 
development of tumors at the lymph nodes and within 
the lungs.27,31 As such, the tumor cell line was dubbed the 
MATLyLu or “metastatic anaplastic tumor capable of spread-
ing to the lymph nodes and lungs” cell line.27 MATLyLu 
(MLL) cells have an in vitro doubling time of 19.7 hours. 
Also, MLL cells are characterized as spindle or polygonal 
shaped and possess large nuclei.31
Meloxicam is a nonsteroidal anti-inflammatory drug that is 
produced from enolic acid.32 The chemical name of meloxicam 
is 4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-
benzo-thiazine-3-carboxamide-1,1-dioxide.33 Meloxicam 
preferentially inhibits the activity of COX-2 over COX-1, 
particularly at lower therapeutic doses.34,35 This preferential 
inhibition of COX-2 is likely due to the unique structure of 
meloxicam. In studies where the 4′ isomer of meloxicam is 
modified, COX-2 specificity is lost.36 Meloxicam provides 
analgesia through the inhibition of COX-2 enzymatic activ-
ity.32,37 Furthermore, meloxicam has demonstrated inhibitory 
effects on cancer growth as seen in studies on colorectal and 
nonsmall cell lung cancer cells.38,39 However, to date, no stud-
ies have been performed to evaluate the effects of meloxicam 
on CIBP. As such, this study is novel in its charge to evaluate 
the effects of meloxicam in a model of CIBP.
Pre-existing tumors in the breast, prostate, and lung com-
monly metastasize to axial skeletal components, including 
the vertebrae. Vertebral bodies are comprised mainly of 
trabecular bone surrounded by a cortical bone shell. The 
distal femoral epiphysis, an appendicular skeletal component, 
consists of trabecular bone surrounded by a dense cortical 
bone shell. Within the animal model utilized in this project, 
the distal femoral epiphysis acts as a model for the metastasis 
of a primary tumor (prostate) to the vertebrae. As a result, 
the nociceptive consequences of prostate cancer metastasis 
can be studied. Moreover, the specific placement of cancer 
cells within the rat femur allows the tumor to develop over 
a longer period than would be possible in the confined rat 
vertebrae. Due to its proximity to the spinal cord, even small 
tumor growth within the vertebrae of the rat could have 
immediate detrimental consequences. As such, the develop-
ment of tumors within the vertebrae of rats would likely 
require euthanasia prior to or immediately following the 
commencement of behavioral tests. However, the placement 
of tumor cells within the femur would allow tumor growth 
over a longer period of time facilitating data collection. It 
was hypothesized that injection of MLL cells into the distal 
femoral epiphysis of a rat results in the production of a bone 
tumor that leads to the generation of nociceptive behaviors.
Materials and methods
MLL cell maintenance
Based on confluence, flasks containing cultured MLL cells 
were split every third to fourth day. Fresh media (RPMI 
1640; Sigma-Aldrich Canada Ltd, Oakville, ON, Canada) 
was warmed for approximately 30 minutes at 36°C prior 
to use. Frozen trypsin (Gibco 15400, 0./E5% trypsinDTA; 
Invitrogen Canada Inc, Burlington, ON, Canada) was also 
warmed for approximately 30 minutes at 36°C prior to use. 
Approximately 2 mL of trypsin was flushed over the cell 
monolayer. Fresh media was then added to incubating flasks Journal of Pain Research 2010:3 submit your manuscript | www.dovepress.com
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to inactivate trypsin. Cell and media mix was then transferred 
via sterile pipette to new sterile T-75 flasks and returned to 
the cell incubator.
Model induction-MLL cell preparation
Media from growth flasks was removed via sterile pipette 
prior to addition of 2 mL of trypsin. Growth flasks were 
then gently rocked and left at room temperature for approxi-
mately 3–5 minutes. Fresh media (8 mL) was then flushed 
over the growth surface in order to inactivate trypsin. For 
one flask, 10 mL of the cell suspension was placed into a 
50 mL conical tube topped up to 20 mL with fresh media. 
After mixing, 50 µL of the cell suspension was removed in 
order to facilitate cell counting. The cell suspension was 
then centrifuged at 1000 rpm for 5 minutes to induce pellet 
formation. Following centrifugation, the supernatant fraction 
was carefully removed via sterile pipette. A predetermined 
volume of phosphate-buffered saline (PBS; vehicle) was 
then added to the pellet to allow for a cell concentration of 
1.0 × 107 cells/mL. MLL cells were then resuspended within 
PBS with use of a sterile pipette. For vehicle injections, fresh 
PBS was transferred to a sterile flask with use of a sterile 
pipette and sealed within a biological safety cabinet.
Animals
All experiments were performed on male Copenhagen 
rats (Harlan Laboratories Inc., Indianapolis, IN) weighing 
225–275 g. All rats were housed in a controlled environment 
with a 12-hour rotating light and dark cycle. Food and water 
were provided ad libitum. Experiments were reviewed and 
approved by the Animal Research Ethics Board at McMaster 
University. All animals were cared for and used in accordance 
with The Care and Use of Experimental Animals, Volumes 1 
and 2, of the Canadian Council on Animal Care.
induction of model
Anesthesia of rats was achieved with gaseous isoflurane and 
oxygen mixture. The right hind leg (ipsilateral) femur/tibia 
joint was flexed from 45° to 55° allowing distal patellar move-
ment. A 25 ga needle was aligned parallel to the long axis 
of the ipsilateral femur, between both the medial and lateral 
condyles. Following insertion through cutaneous tissue, the 
needle was rotated manually to induce cavity formation 
within the epiphysis. MLL cells (1.0 × 106) suspended in 
0.10 mL PBS were then injected into the bone for tumor 
induction. Control rats received a 0.10 mL PBS injection into 
the epiphysis. Volume of injected material was minimized 
to ensure that it remained within the penetrated epiphysis. 
Accessory surgical instrument, procedures, and materials 
were avoided in order to minimize damage to tissue and 
ensure observed nociceptive behaviors were due to tumor 
growth within the epiphysis.
Drug administration
Meloxicam (meloxicam sodium salt hydrate; Sigma-Aldrich 
Canada Ltd) was dissolved in 5% methyl cellulose (M70140-
500MG powder; Sigma-Aldrich Canada Ltd,) prepared on 
testing days prior to commencement of behavioral tests. 
Meloxicam was administered as 5, 2.5, or 1 mg/kg intra-
peritoneal injection. In order to allow for meloxicam to be 
metabolized and take effect, behavioral tests began 45 min-
utes following meloxicam or PBS injection.
Characterization of model
Baseline (BL) readings were recorded from all rats from 
the incapacitance and Randall–Selitto tests prior to model 
induction. Results from the tests were then recorded from 
all rats on days 3, 7, 10, and 13 post-induction. On experi-
mental days, all rats first underwent the incapacitance test 
followed then by the Randall–Selitto test. It was determined 
experimentally that 13 days following model induction, rats 
experienced serious and unacceptable detrimental effects 
as a result of tumor growth. These effects were observed in 
behaviors that included, but were not limited to, previously 
unobserved defensive posture in the presence of the experi-
menter, vocalization upon palpation and severely reduced 
ambulation. As such, due to ethical considerations, it was 
determined that all experiments would be terminated 13 days 
following model induction.
A Dual Channel Weight Averager, Incapacitance Tester 
(Linton Instrumentation, Norfolk, UK), was utilized to mea-
sure differential hind leg paw weight distribution. Prior to data 
collection, rats were placed in a clear plastic holder. Below 
the level of the holder and under the rat, two force transducer 
pads measured the weight placed upon each hind leg. The 
forelimbs of rats were rested halfway upon the leading edge 
of the plastic holder. An individual recording comprised of 
the average weight (in grams) placed on each hind paw that 
was automatically recorded over a preset period of 3 seconds 
for each recording. On each testing day, three individual 
recordings were obtained per rat.
An IITC Model 2500 Randall–Selitto Paw Pressure Meter 
(IITC Life Science Inc., Woodland Hills, CA) was utilized for 
data collection in order to examine skin hyperalgesia. Due to 
the diameter of the rat femur (which progressively increased 
following tumor development), rat paws were tested. Rats Journal of Pain Research 2010:3 submit your manuscript | www.dovepress.com
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were lightly restrained within a cloth with the ipsilateral 
hind leg exposed and free to move. This hind paw was placed 
on the paw pressure clamp while the plinth was depressed onto 
the anterior surface of the paw. The minimum force (in grams) 
applied to the paw prior to its voluntary withdrawal and subse-
quent dislodging from the pressure clamp was automatically 
recorded. On each testing day, three individual recordings 
were obtained per rat taken 2 minutes apart.
On all testing days prior to the commencement of 
behavioral tests, the weight of all rats was measured and 
recorded.
histology
Upon euthanasia, both the ipsilateral and contralateral hind 
legs of rats were immediately dissected and shed of cutaneous 
tissue and muscle. Following dissection, all bone samples 
were immediately fixed in a 10% formalin solution in PBS 
and subsequently decalcified in a 900 mL 4% formalin/10% 
ethylenediaminetetraacetic acid (EDTA) solution. Samples 
remained within the solution for 4 weeks with the replace-
ment of fresh solution occurring every third day.
Once decalcification was complete, samples were further 
processed in paraffin wax. Sections were placed on ice cubes 
to cool over a period of 10–15 minutes. When cool, sections 
were fixed to a microtome (Reichert-Jung 2040 Microtome; 
Reichert Inc., Depew, NY) and 3 µm sections of tissue were 
produced. Sections were then placed onto a preheated water 
bath. Tissue was fixed onto the surface of appropriately labeled 
glass slides and allowed to dry overnight.
Glass slides possessing sectioned tissue were placed into 
an oven at 45°C for 20–25 minutes prior to hematoxylin and 
eosin (H&E) staining. Slides were subsequently removed 
from the oven and allowed to cool for 10–15 minutes. 
Once cool, slides were placed within a slide holder and 
washed until clear in three consecutive changes of xylene 
for 5 minutes each. The slides were then washed until clear 
within 100% ethanol, 100% ethanol, 70% ethanol, and 50% 
ethanol sequentially. Following ethanol washes, slides were 
immersed within water then treated in hematoxylin (Gill 
Number 3, GHS332-1 L; Sigma-Aldrich Canada Ltd), diluted 
with water to a ratio of 1:2 for 3 minutes to induce staining, 
followed by immersion in water. Slides were then immersed 
within alkaline lithium carbonate for 10 seconds to change 
the color of the hematoxylin stain to blue. Lithium carbonate 
treatment was followed by a water wash. Slides were then 
immersed for 45 seconds in eosin solution. Eosin (diluted 
1:3 in 80% ethanol) treatment was then followed with two 
washes until clear of 96% ethanol, three changes of 100% 
ethanol, and two changes of xylene. Cover slips were then 
mounted on top of slides with Permount (SP15-100 Toluene 
Solution; Fisher Scientific Company, Toronto, ON, Canada) 
and allowed to dry overnight.
X-ray radiographs
Following the completion of all behavior tests, rats were 
euthanized and hind limbs were immediately dissected and 
placed within 10% formalin. High-resolution radiographic 
scans of dissected rat femurs were acquired with a Faxitron 
X-ray MX-20 system (Faxitron, Lincolnshire, IL) on Kodak 
MIN-R 2000 Mammography Film (MIN-R 2000 Mammog-
raphy Film, Kodak, Rochester, NY).
CT scans
Following the completion of all behavior tests, rats were 
euthanized, and hind limbs were immediately dissected and 
placed in 10% formalin. Computed tomography (CT) scans 
were obtained with a GammaMI Gamma Medica X-SPECT 
Dedicated Animal Imaging unit (Gamma Medica-Ideas Ltd., 
London, ON, Canada). Data for each sample were recon-
structed with Cobra_EXXIM software (Exxim Computing 
Corporation, Pleasanton, CA).
statistical analysis
Behavior data are presented as the mean ± standard devia-
tion (SD). Differences in bodyweight data are presented as 
differences from BL values ± SD. Statistically significant 
differences between groups were determined with two-way 
analysis of variance (ANOVA) followed by Bonferroni 
post hoc analysis. A two-tailed P-value of less than 0.05 was 
considered significant.
Results
h&e stain
The H&E-stained sections of the ipsilateral distal femur from 
PBS-injected rats indicated the presence of healthy marrow 
within the epiphysis and diaphysis. Healthy trabecular bone 
was also visible in sections from the PBS-injected rats. Sec-
tions of the ipsilateral distal femur from MLL cell injected 
rats indicated tumor replacement of marrow within the epi-
physis (Figure 1). Also visible within the epiphysis of MLL 
cell injected rats was eroded trabecular bone (Figure 1). As 
in the sections from PBS-injected rats, those from MLL-
injected rats revealed the presence of healthy marrow within 
the femoral diaphysis.Journal of Pain Research 2010:3 submit your manuscript | www.dovepress.com
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PBS-injected rats indicated healthy ipsilateral hind legs with 
a lack of bone degradation in the distal epiphysis. Scans 
from MLL cell injected rats indicated extensive osteolytic 
damage to the distal epiphysis of the ipsilateral hind leg   
(Figure 3).
Difference in bodyweight
Figure 4 shows the change in bodyweight from BL of rats 
following PBS or MLL cell injection. The difference in this 
weight change in the MLL group was significantly differ-
ent from that in the PBS injected group on days 10 and 13 
(P , 0.001). Weight gain in the MLL cell injected group 
plateaued between days 7 and 10 with a loss in weight 
between days 10 and 13. PBS-injected rats exhibited normal 
weight gain over time associated with normal growth. Data 
are displayed as mean ± SD.
incapacitance test
Prior to model induction, both control and model rats were 
observed to place weight evenly on both hind legs, thus dis-
playing a differential weight distribution of approximately 
zero when placed in the chamber. Figure 5A shows changes 
in hind limb weight distribution (contralateral–ipsilateral) 
following PBS or MLL cell injection. The MLL cell injected 
group was significantly different from the PBS-injected group 
on days 7, 10, and 13 (P , 0.001). The MLL cell-injected 
rats preferentially placed weight on the contralateral hind leg 
after day 3. PBS injected rats maintained BL level of weight   
distribution.
Randall–selitto test
Prior to model induction, both groups of rats voluntarily with-
drew their ipsilateral paw at approximately 130 g. Figure 5B 
depicts change in ipsilateral paw withdrawal threshold from 
the Randall–Selitto pressure clamp following PBS or MLL 
cell injection. The MLL cell-injected group was significantly 
different from PBS-injected group on days 7, 10, and 13 
(P , 0.001). PBS-injected group maintained BL level of 
withdrawal threshold.
effect of meloxicam in the  
incapacitance test
Figure 6A shows hind limb weight distribution (contralateral-
ipsilateral) following MLL cell injection at different doses 
of meloxicam. The vehicle group was given a 5% methyl 
cellulose solution. The 5.0 mg/kg group was significantly 
different from the 2.5 mg/kg and 1.0 mg/kg groups and the 
X-ray radiographs
Comparisons were made of radiographs of the ipsilateral 
hind legs from PBS and MLL cell injected rats. Representa-
tive radiographs are illustrated in Figure 2. PBS-injected rats 
exhibited normal bone density and structure in the ipsilateral 
hind leg. Clinical features of structural changes visible in 
the radiographs of MLL cell injected ipsilateral hind leg 
illustrated in Figure 2 were not observed in the ipsilateral 
hind leg of vehicle-injected rats.
CT scans
Comparisons were made of CT scans of the ipsilateral hind 
legs from PBS and MLL cell injected rats. CT scans from 
A
B
Figure 1 hematoxylin and eosin (h&e) stains of ipsilateral distal femur. histological 
sections of the ipsilateral femoral epiphysis from vehicle (A) and MLL (MATLyLu) 
cell injected (B) rats. Visible in the figure is eroded trabecular bone (arrow). Sections 
were stained with h&e. M, marrow, B, bone, T, tumor. Bar represents 100 µm.Journal of Pain Research 2010:3 submit your manuscript | www.dovepress.com
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vehicle group on days 10 and 13 (P , 0.001). The 5.0 mg/kg 
group was significantly different from the 1.0 mg/kg group on 
day 7 (P , 0.01). The 5.0 mg/kg group was significantly dif-
ferent from the PBS group on days 7, 10, and 13 (P , 0.001). 
The 2.5 mg/kg group was significantly different from the 
1.0 mg/kg group on day 7 (P , 0.05). The 2.5 mg/kg group 
was significantly different from the PBS group on days 7, 
10, and 13 (P , 0.001). The 1.0 mg/kg group was signifi-
cantly different from the PBS group on days 7, 10, and 13 
(P , 0.001). The vehicle group was significantly different 
A
B
Figure 2 Radiographs of rat ipsilateral hind legs. Radiographs of the ipsilateral 
hind leg from vehicle (A) and MATLyLu (MLL) cell injected (B) rats displaying 
structural changes following model induction. Compared to vehicle, the radiograph 
from the MLL cell injected rat displayed acute osteopenia within the distal portion 
of the ipsilateral femur involving the distal femoral metadiaphysis (black arrow), 
metaphysis (white arrow), and epiphysis (black hatched arrow). Also visible in the 
radiograph of the MLL cell injected ipsilateral hind leg was cortical destruction in 
the anterior aspect of the metaphysis and metadiaphysis with periosteal reaction 
(white arrowhead). Joint effusion within the MLL cell-injected ipsilateral femur was 
also visible in the radiograph (black arrowhead).
AB
Figure 3 Computed tomography scans of rat ipsilateral hind legs. (A) Anterior view of 
the ipsilateral leg from a vehicle injected rat. (B) Anterior view of the ipsilateral leg from 
a MATLyLu (MLL) cell-injected rat. structural damage in the form of trabecular and 
periosteal bone erosion is visible in the ipsilateral epiphysis from the MLL cell-injected 
rat with an absence of damage in the same region from the vehicle-injected rat.
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Figure 4 Difference in bodyweight following model induction. Change in bodyweight 
in vehicle (n = 12, ○, 223.5 g at BL) and MLL cell (n = 10, ●, 228.4 g at BL) rats 
following injection. Data are displayed as mean ± sD. ***P , 0.001.
Abbreviations: BL, baseline from reading from each group; MLL, MATLyLu; sD, 
standard deviation.Journal of Pain Research 2010:3 submit your manuscript | www.dovepress.com
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from the PBS group on days 7, 10, and 13 (P , 0.001). The 
5.0 mg/kg group reduced the difference in hind leg weight 
distribution when compared with the 2.5 mg/kg, 1.0 mg/kg, 
vehicle, and PBS groups. Changes in weight difference in 
the 5.0 mg/kg group plateaus from day 7 to day 13. Thus, 
the 5.0 mg/kg dose of meloxicam appears to be highly effec-
tive in reducing paw weight imbalance in the incapacitance   
test.
effect of meloxicam in the  
Randall–selitto test
Figure 6B illustrates the ipsilateral hind paw withdrawal 
threshold from the Randall–Selitto pressure clamp follow-
ing different doses of meloxicam in the MLL cell-injected 
group and the group receiving PBS alone. The vehicle group 
received a 5% methyl cellulose solution. The 5.0 mg/kg group 
was significantly different from the 2.5 mg/kg, 1.0 mg/kg, 
and vehicle groups on days 7, 10, and 13 (P , 0.001). The 
5.0 mg/kg group was significantly different from the PBS 
group on day 13 (P , 0.001). The 2.5 mg/kg group was 
significantly different from the 1.0 mg/kg and vehicle groups 
on day 7 (P , 0.001). The 2.5 mg/kg group was significantly 
different from the 1.0 mg/kg group on day 10 (P , 0.001). 
The 2.5 mg/kg group was significantly different from the 
PBS group on days 7, 10, and 13 (P , 0.001). The 1.0 mg/kg 
group was significantly different from the PBS group on days 
7, 10, and 13 (P , 0.001). The vehicle group was signifi-
cantly different from the PBS group on days 7, 10, and 13 
(P , 0.001). Rats receiving 5.0 mg/kg meloxicam maintained 
A
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Figure 5 (A) incapacitance test results. Figure displays the differential hind leg 
weight distribution in vehicle (n = 8, ○) and MLL (n = 10, ●) cell injected rats. hind 
limb weight difference was measured in grams (g). Data are displayed as mean ± sD. 
At BL, both groups displayed no significant difference in weight distribution between 
both hind legs. Dotted line indicates point of model induction. ***P , 0.001. (B) 
Randall–selitto test results. Figure displays the paw withdrawal threshold in vehicle 
(n = 8, ○) and MLL (n = 10, ●) cell-injected rats. Paw withdrawal threshold was 
measured in grams (g) of force. Data are displayed as mean ± sD. Dotted line 
indicates point of model induction. ***P , 0.001. 
Abbreviations: BL, baseline from reading from each group; MLL, MATLyLu; sD, 
standard deviation.
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Figure  6  (A)  Meloxicam  effects  in  incapacitance  test.  effect  of  meloxicam  on 
differential hind leg weight distribution in PBs-injected (ie, no MLL cells), vehicle (ie, 
0.5% methyl cellulose to MLL cell-injected rats) and in MLL cell-injected rats. PBs 
(○, n = 8), vehicle (♦, n = 9), 1.0 mg/kg meloxicam (▼, n = 9), 2.5 mg/kg meloxicam 
(▲, n = 8) and 5.0 mg/kg meloxicam (■, n = 7) groups are displayed. Data are 
displayed  as  mean  ±  sD.  ***P  ,  0.001.  B)  Meloxicam  effects  in  Randall–selitto 
test. Change in ipsilateral hind paw withdrawal threshold from the Randall–selitto 
pressure  clamp  following  administration  of  meloxicam  or  0.5%  methyl  cellulose 
solution. Vehicle (○, n = 8), PBs (♦, n = 9), 1.0 mg/kg meloxicam (▼, n = 9), 2.5 mg/kg 
meloxicam (▲, n = 8) and 5.0 mg/kg meloxicam (■, n = 7) groups are displayed. Data 
are displayed as ± sD. ***P , 0.001. 
Abbreviations: BL, baseline from reading from each group; MLL, MATLyLu; PBs, 
phosphate buffered saline; sD, standard deviation.Journal of Pain Research 2010:3 submit your manuscript | www.dovepress.com
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BL withdrawal threshold from the Randall–Selitto pressure 
clamp until day 10 of testing. Thus, it appears that 5.0 mg/kg 
of meloxicam was effective in delaying the decrease in with-
drawal threshold.
Discussion
In this study, injection of MLL cells into the rat femoral 
epiphysis resulted in an aggressive osteolytic lesion. The 
resultant tumor formation led to trabecular bone degradation 
and the development of nociceptive behaviors.
Tumor growth as a result of MLL cell injection resulted 
in the appearance of nociceptive behaviors in injected rats. 
The incapacitance test demonstrated that rats receiving the 
MLL cell injection progressively favored the contralateral 
hind leg over the course of the experiment. Supporting this 
observation, Niiyama and colleagues recently demonstrated 
that injection of murine sarcoma cells NCTC 2472 into the 
mouse femur resulted in severely reduced weight bearing on 
the ipsilateral hind paw during standing.40 It has also been 
independently observed that intrafemoral injection of the 
NCTC 2472 murine sarcoma cells into rats resulted in the 
reduced weight-bearing ability on the ipsilateral hind leg.41 
Medhurst and colleagues also demonstrated that following 
intra tibial injection of MRMT-1 rat mammary gland car-
cinoma cells the weight-bearing ability on the ipsilateral 
hind leg was reduced progressively over the course of the 
experiment.42 A similar progressive loss in weight-bearing 
ability in the ipsilateral hind leg following tumor formation 
was observed with intra femoral Walker-256 mammary 
gland cell injection.43
Moreover, tumor growth also reduced significantly 
the paw withdrawal threshold of the ipsilateral hind paw. 
Bone structure, growth of the tumor, and an inflammatory 
response are likely contributors to the observed nociceptive 
behaviors. The periosteum of the femur is richly innervated 
by primary afferent sensory nerve fibers. There are also 
peripheral nociceptive neurons located in the area of the 
patella and distal femur. The progressively growing tumor 
mass could have placed pressure upon the periosteal and 
peripheral nerve fibers resulting in their sensitization. 
Also, the presence of inflammatory factors leading to 
inflammation within the immediate area of tumor growth 
could have resulted in the sensitization of neurons. It has 
recently been demonstrated that the inflammatory mediator 
interleukin-1ß is increased in the area of an induced tibial 
osteosarcoma and within the inflamed paws of injected 
mice.44 Similar results have also been published by Zhang 
and colleagues.45
Conclusion
The findings from this project demonstrate that intra-femoral 
MLL cell injection leads to tumor formation and progres-
sive bone destruction. The induced bone damage results in 
a progressive distribution of weight from the ipsilateral to 
the contralateral hind leg and a reduction in the ipsilateral 
paw withdrawal threshold. To our knowledge, this is the first 
study to provide a complete analysis of histological and radio-
graphic results of rodent femurs combined with behavioral 
analysis in a model for CIBP induced by prostate cancer cell 
lines and via measurement of nociceptive scores. This model 
may be used in the future for therapeutic studies examining 
the pain associated with cancer induced bone metastasis.
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